177 related articles for article (PubMed ID: 24252082)
1. Kv1.3 blockers ameliorate allergic contact dermatitis by preferentially suppressing effector memory T cells in a rat model.
Ueyama A; Imura K; Kasai-Yamamoto E; Tai N; Nagira M; Shichijo M; Yasui K
Clin Exp Dermatol; 2013 Dec; 38(8):897-903. PubMed ID: 24252082
[TBL] [Abstract][Full Text] [Related]
2. Targeting effector memory T cells with the small molecule Kv1.3 blocker PAP-1 suppresses allergic contact dermatitis.
Azam P; Sankaranarayanan A; Homerick D; Griffey S; Wulff H
J Invest Dermatol; 2007 Jun; 127(6):1419-29. PubMed ID: 17273162
[TBL] [Abstract][Full Text] [Related]
3. Imaging of effector memory T cells during a delayed-type hypersensitivity reaction and suppression by Kv1.3 channel block.
Matheu MP; Beeton C; Garcia A; Chi V; Rangaraju S; Safrina O; Monaghan K; Uemura MI; Li D; Pal S; de la Maza LM; Monuki E; Flügel A; Pennington MW; Parker I; Chandy KG; Cahalan MD
Immunity; 2008 Oct; 29(4):602-14. PubMed ID: 18835197
[TBL] [Abstract][Full Text] [Related]
4. Targeting effector memory T-cells with Kv1.3 blockers.
Wulff H; Pennington M
Curr Opin Drug Discov Devel; 2007 Jul; 10(4):438-45. PubMed ID: 17659485
[TBL] [Abstract][Full Text] [Related]
5. Blocking KV1.3 channels inhibits Th2 lymphocyte function and treats a rat model of asthma.
Koshy S; Huq R; Tanner MR; Atik MA; Porter PC; Khan FS; Pennington MW; Hanania NA; Corry DB; Beeton C
J Biol Chem; 2014 May; 289(18):12623-32. PubMed ID: 24644290
[TBL] [Abstract][Full Text] [Related]
6. Characterization of the functional properties of the voltage-gated potassium channel Kv1.3 in human CD4+ T lymphocytes.
Hu L; Pennington M; Jiang Q; Whartenby KA; Calabresi PA
J Immunol; 2007 Oct; 179(7):4563-70. PubMed ID: 17878353
[TBL] [Abstract][Full Text] [Related]
7. Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune diseases.
Schmitz A; Sankaranarayanan A; Azam P; Schmidt-Lassen K; Homerick D; Hänsel W; Wulff H
Mol Pharmacol; 2005 Nov; 68(5):1254-70. PubMed ID: 16099841
[TBL] [Abstract][Full Text] [Related]
8. Prolonged immunomodulation in inflammatory arthritis using the selective Kv1.3 channel blocker HsTX1[R14A] and its PEGylated analog.
Tanner MR; Tajhya RB; Huq R; Gehrmann EJ; Rodarte KE; Atik MA; Norton RS; Pennington MW; Beeton C
Clin Immunol; 2017 Jul; 180():45-57. PubMed ID: 28389388
[TBL] [Abstract][Full Text] [Related]
9. Kv1.3 potassium channels as a therapeutic target in multiple sclerosis.
Rangaraju S; Chi V; Pennington MW; Chandy KG
Expert Opin Ther Targets; 2009 Aug; 13(8):909-24. PubMed ID: 19538097
[TBL] [Abstract][Full Text] [Related]
10. Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases.
Beeton C; Pennington MW; Wulff H; Singh S; Nugent D; Crossley G; Khaytin I; Calabresi PA; Chen CY; Gutman GA; Chandy KG
Mol Pharmacol; 2005 Apr; 67(4):1369-81. PubMed ID: 15665253
[TBL] [Abstract][Full Text] [Related]
11. Kv1.3 in psoriatic disease: PAP-1, a small molecule inhibitor of Kv1.3 is effective in the SCID mouse psoriasis--xenograft model.
Kundu-Raychaudhuri S; Chen YJ; Wulff H; Raychaudhuri SP
J Autoimmun; 2014 Dec; 55():63-72. PubMed ID: 25175978
[TBL] [Abstract][Full Text] [Related]
12. Immunosuppressive evidence of Tityus serrulatus toxins Ts6 and Ts15: insights of a novel K(+) channel pattern in T cells.
Pucca MB; Bertolini TB; Cerni FA; Bordon KC; Peigneur S; Tytgat J; Bonato VL; Arantes EC
Immunology; 2016 Feb; 147(2):240-50. PubMed ID: 26595158
[TBL] [Abstract][Full Text] [Related]
13. Kv1.3-blocking 5-phenylalkoxypsoralens: a new class of immunomodulators.
Vennekamp J; Wulff H; Beeton C; Calabresi PA; Grissmer S; Hänsel W; Chandy KG
Mol Pharmacol; 2004 Jun; 65(6):1364-74. PubMed ID: 15155830
[TBL] [Abstract][Full Text] [Related]
14. Kv1.3 channel-blocking immunomodulatory peptides from parasitic worms: implications for autoimmune diseases.
Chhabra S; Chang SC; Nguyen HM; Huq R; Tanner MR; Londono LM; Estrada R; Dhawan V; Chauhan S; Upadhyay SK; Gindin M; Hotez PJ; Valenzuela JG; Mohanty B; Swarbrick JD; Wulff H; Iadonato SP; Gutman GA; Beeton C; Pennington MW; Norton RS; Chandy KG
FASEB J; 2014 Sep; 28(9):3952-64. PubMed ID: 24891519
[TBL] [Abstract][Full Text] [Related]
15. K
Veytia-Bucheli JI; Jiménez-Vargas JM; Melchy-Pérez EI; Sandoval-Hernández MA; Possani LD; Rosenstein Y
Cell Commun Signal; 2018 Aug; 16(1):45. PubMed ID: 30107837
[TBL] [Abstract][Full Text] [Related]
16. T Cell Subset and Stimulation Strength-Dependent Modulation of T Cell Activation by Kv1.3 Blockers.
Fung-Leung WP; Edwards W; Liu Y; Ngo K; Angsana J; Castro G; Wu N; Liu X; Swanson RV; Wickenden AD
PLoS One; 2017; 12(1):e0170102. PubMed ID: 28107393
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics, toxicity, and functional studies of the selective Kv1.3 channel blocker 5-(4-phenoxybutoxy)psoralen in rhesus macaques.
Pereira LE; Villinger F; Wulff H; Sankaranarayanan A; Raman G; Ansari AA
Exp Biol Med (Maywood); 2007 Nov; 232(10):1338-54. PubMed ID: 17959847
[TBL] [Abstract][Full Text] [Related]
18. Toxins Targeting the Kv1.3 Channel: Potential Immunomodulators for Autoimmune Diseases.
Zhao Y; Huang J; Yuan X; Peng B; Liu W; Han S; He X
Toxins (Basel); 2015 May; 7(5):1749-64. PubMed ID: 25996605
[TBL] [Abstract][Full Text] [Related]
19. A Kv1.3 channel-specific blocker alleviates neurological impairment through inhibiting T-cell activation in experimental autoimmune encephalomyelitis.
Yuan XL; Zhao YP; Huang J; Liu JC; Mao WQ; Yin J; Peng BW; Liu WH; Han S; He XH
CNS Neurosci Ther; 2018 Oct; 24(10):967-977. PubMed ID: 29577640
[TBL] [Abstract][Full Text] [Related]
20. Rutin suppresses atopic dermatitis and allergic contact dermatitis.
Choi JK; Kim SH
Exp Biol Med (Maywood); 2013 Apr; 238(4):410-7. PubMed ID: 23760007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
